Novo Nordisk ASHAM:NOVA +2.90%83 PS Ratio is 4.45 as of Jul. 04, 2026, which is 43% below its 10-year median of 7.81. GuruFocus rates HAM:NOVA with a GF Score™ of 83/100 and a GF Value™ of €121.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 950 Drug Manufacturers companies, Novo Nordisk AS ranks worse than 71.26% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Novo Nordisk AS's share price is €43.94.
Novo Nordisk AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €9.87. Hence, Novo Nordisk AS's PS Ratio for today is 4.45.
The historical rank and industry rank for Novo Nordisk AS's PS Ratio or its related term are showing as below:
HAM:NOVA'
s PS Ratio Range Over the Past 10 Years
Min: 3.21 Med: 7.81 Max: 18.46
Current: 4.44
During the past 13 years, Novo Nordisk AS's highest PS Ratio was 18.46. The lowest was 3.21. And the median was 7.81.
HAM:NOVA's PS Ratio is ranked worse than 71.26% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs HAM:NOVA: 4.44
Novo Nordisk AS revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Novo Nordisk AS was 8.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 21.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 23.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.60% per year.
During the past 13 years, Novo Nordisk AS's highest 3-Year average Revenue per Share Growth Rate was 127.90% per year. The lowest was -46.20% per year. And the median was 12.40% per year.
Back to Basics: PS Ratio
Novo Nordisk AS (HAM:NOVA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Novo Nordisk AS PS Ratio Related Terms
Novo Nordisk AS PS Ratio Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Novo Nordisk AS's Share Price of today is €43.94. Novo Nordisk AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.87.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Novo Nordisk AS (HAM:NOVA) has a PS Ratio of 4.45 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Novo Nordisk AS and its competitors. This is 43% below median its historical median of 7.81. Over the past decade, Novo Nordisk AS's PS Ratio has ranged from 3.21 to 18.46. According to the industry distribution chart, Novo Nordisk AS ranks #677 out of 950 companies in the Drug Manufacturers industry, placing it in the top 71.3%.
Is Novo Nordisk AS's PS Ratio too high?
Novo Nordisk AS's current PS Ratio of 4.45 is 43% below median its 10-year median of 7.81. Over the past 10 years, this metric has ranged from a low of 3.21 to a high of 18.46. The Drug Manufacturers industry median PS Ratio is 2.32. Novo Nordisk AS's value of 4.45 is 92.2% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #677 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #677 out of 950 companies for PS Ratio. This places Novo Nordisk AS in the lower half of its industry. The industry median PS Ratio is 2.32. Novo Nordisk AS's value of 4.45 is 92.2% above this benchmark. Historically, Novo Nordisk AS's own PS Ratio has ranged from 3.21 to 18.46 over the past decade. While the company's 10-year median is 7.81 vs. the industry median of 2.32, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current PS Ratio of 4.45 is 92.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current PS Ratio is 4.45, which is 43% below median its own 10-year median of 7.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (HAM:NOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is €121.46, compared to a current price of €43.94 — trading 63.8% below its estimated fair value. The current PS Ratio is 4.45, which is 43% below median its 10-year median of 7.81 and 92.2% above the Drug Manufacturers industry median of 2.32. Novo Nordisk AS's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Novo Nordisk AS (HAM:NOVA), the current PS Ratio is 4.45 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €43.94 is trading 63.8% below its estimated GF Value™ of €121.46.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for HAM:NOVA:
PS Ratio: 4.45 (43% below median its 10-year median of 7.81)
GF Value™: €121.46 vs. price of €43.94 (63.8% below fair value)
Industry Position: 92.2% above the Drug Manufacturers median (#677 of 950)
No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
83GF Score
Get the complete analysis for HAM:NOVA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NOVA has been successfully added to your 
